| Followers | 227 |
| Posts | 12530 |
| Boards Moderated | 0 |
| Alias Born | 08/14/2009 |
Friday, June 07, 2013 3:59:16 PM
Riding up the Bollinger bands like last time!!!
Day to day up and flat as per bands!!!
http://stockcharts.com/h-sc/ui?s=SNGX&p=D&b=5&g=0&id=p00429915336&a=305371063
GLTA
ID
Day to day up and flat as per bands!!!
http://stockcharts.com/h-sc/ui?s=SNGX&p=D&b=5&g=0&id=p00429915336&a=305371063
GLTA
ID
Recent SNGX News
- Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo • PR Newswire (US) • 05/26/2026 11:30:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:16:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:14:13 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:12:12 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/08/2026 08:10:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:05:35 PM
- Soligenix Announces Recent Updates and First Quarter 2026 Financial Results • PR Newswire (US) • 05/08/2026 11:30:00 AM
- SNGX Phase 3 Trial Halted — HyBryte Setback Puts Strategy in Question • IH Market News • 04/28/2026 03:06:46 PM
- SNGX Phase 3 Trial Halted on HyBryte • IH Market News • 04/28/2026 03:06:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:30:13 AM
- Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma • PR Newswire (US) • 04/28/2026 11:30:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/03/2026 04:15:15 AM
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy • PR Newswire (US) • 04/02/2026 11:30:00 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:13:29 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:11:25 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:09:30 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/31/2026 08:08:14 PM
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results • PR Newswire (US) • 03/31/2026 11:30:00 AM
- Soligenix secures EU orphan drug designation for Behçet’s disease therapy • IH Market News • 03/26/2026 02:15:07 PM
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease • PR Newswire (US) • 03/26/2026 11:30:00 AM
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 • PR Newswire (US) • 03/23/2026 11:30:00 AM
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
